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Abstract
While whole killed, whole protein, or live attenuated vaccines were the standard bearers for protective vaccines in 
the last century, there are concerns about their safety. New vaccine design techniques are contributing to an 
emphasis on vaccines developed using the minimum essential subset of T- and B-cell epitopes that comprise the 
“immunome.” We have used bioinformatics sequence analysis tools, epitope-mapping tools, microarrays and high-
throughput immunology assays to identify the minimal essential vaccine components for smallpox, tularemia, 
Helicobacter pylori and tuberculosis vaccines. As will be described in this review, this approach has resulted in the 
development of four immunome-derived epitope-driven vaccines (ID-EDV); three of these proved protective against
viral or bacterial challenge. Protective efficacies of 100% (vaccinia), 90% (H. pylori), and 57% (tularemia) were 
achieved in HLA-transgenic (humanized) mouse models and the p27 knockout mouse (for H. pylori). Such 
immunome-derived vaccines have a significant advantage over conventional vaccines; the careful selection of the 
components should diminish undesired side effects such as those observed with whole pathogen and protein subunit 
vaccines. Here we summarize data showing prototype ID-ED vaccine protection against lethal challenge with 
vaccinia, tularemia, and H. pylori in a model of infection. The tools that made these successes possible are described 
and the anticipated clinical development of ID-ED vaccines is discussed.
© 2009 Elsevier B.V. 
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1. Rationale for a new approach to vaccines
During the 20th Century, many classic childhood diseases were nearly eradicated in the developing world, but 
many pathogens and emerging infections still remain for which the original attenuation, inactivation, or subunit 
approaches to vaccine development did not work. As pathogens evolve, so must vaccine design. Immunome 
derived, also known as epitope-driven, vaccines represent the next phase of vaccine design. Instead of using whole 
pathogens or proteins, immunome-derived epitope-driven vaccines use the smallest functional unit of immunity, the 
epitope, to tailor an effective immune response [1,2].
One reason to develop immunome-derived epitope-driven vaccines (ID-EDV) is that the safety of live attenuated 
microorganisms or inactivated microorganisms administered through injections has been questioned. Adverse 
incidents have been linked to incomplete attenuation or inactivation of such “whole” bacterial or viral vaccines. 
Evidence is also emerging that cross-reactive epitopes may predispose the vaccinated subject to an altered immune 
response to vaccination, leading to an alteration in the protective effect of the vaccine [3,4]. Additionally, whole-
killed or attenuated vaccines may contain proteins or other components (cell wall lipids, polysaccharides) that elicit 
an undesired immune response. Therefore, as researchers have become more knowledgeable about immune response 
targets and determinants, a more favorable strategy for vaccine development may be to select specific subunits, such 
as T-cell epitopes and B-cell epitopes from microorganisms, and produce them as recombinant vaccines.
Pre-exposure to certain bacteria or viruses may also determine the outcome of vaccination. Such cross-reactive 
immune responses, termed “heterologous immunity,” have now been shown to alter the effectiveness of vaccines 
and therapeutics [5,6] in animal models. Cross-reactive immune responses may also alter immune response to self, 
leading to autoimmune disease, a health problem of steadily increasing proportions that now affects one in twenty 
Americans and Europeans. In-depth studies of autoimmunity have revealed HLA associations and a number of 
environmental triggers [7,8]. In some studies, cross-reactive T-cell responses have been attributed to epitopes 
present in certain vaccines [9]. The relationship between human pathogens, commensal microbes, and the (human) 
self at the T-cell epitope level may deserve more attention than it has received to date.
Critical to the development of ID-EDV has been the elucidation of the ‘correlates of immunity’ for a wide range 
of important human pathogens. The link between epitope-specific responses, establishment of T-cell memory, and 
protection from disease has been confirmed for HIV, hepatitis B (HBV), hepatitis C (HCV), malaria [10-11, 2], and 
other infectious diseases. A number of laboratories are pursuing research supporting the hypothesis that a protective 
immune response to a number of pathogens requires the development of broad T-cell responses to an ensemble of 
different epitopes [13-14,15, 6]. Following exposure to a pathogen, epitope-specific memory T-cell clones are established 
[17]. These clones respond rapidly and efficiently upon subsequent infection, secreting cytokines, killing infected 
host cells, and marshalling other cellular defenses against the pathogen. Indeed, T cells have come to be recognized 
as critical mediators of competent and lasting humoral and cytotoxic immune responses elicited by vaccines [18,19]. 
In-silico epitope-mapping tools are often used to screen large numbers of protein sequences for potential T-cell 
epitopes. In high-throughput screening, small differences in the accuracy of epitope prediction tools can contribute 
to large differences in the cost and time-effort expended on subsequent studies.
The focus on T-cell epitopes for vaccine design catalyzed the development of computer-driven 
(immunoinformatics) methods for defining T-cell epitopes directly from protein sequences. This enabled 
investigations of the role of T-cells to leapfrog directly to the leading edge of immunology and vaccine research. For 
example, the research team of Martin and De Groot at EpiVax, Inc., has developed a suite of computer algorithms 
that can be applied to the development of epitope-based vaccines; this suite includes EpiMatrix, ClustiMer, 
Conservatrix, BlastiMer, Aggregatrix, OptiMatrix, and VaccineCAD [20-21222324 252627 8].
EpiMatrix was first developed in 1996 [29] and subsequently updated for use with Oracle databases by Bill 
Martin [30]. EpiMatrix was recently evaluated for its ability to predict established class I and class II HLA-restricted 
epitopes and these data were compared to an analysis published by Wang et al. [31] and the IEDB [32]. An “area 
under the Receiver Operated Characteristic (ROC) curve” was used to compare EpiMatrix to published data for six 
“supertype” class I and eight archetypal class II EpiMatrix matrices developed in 2008. The analyses were 
performed using published epitope data available in the IEDB as of June 2008 [33]. For Class I and Class II 
predictions, the average area under curve (AUC) values of EpiMatrix were .95 and .78, respectively. These values 
outperform the best tools available (IEDB ANN) as well as additional publicly available tools used in the 
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comparison (RANKPEP, BIMAS, SYFPEITHI, MHC2PRED, MHCPRED, SMM-align, SVRMHC, and 
TEPITOPE). The comparisons are now published [34]. 
In addition to the EpiMatrix algorithm for T-cell epitope identification, the EpiMatrix toolset also includes a set 
of analysis and design tools directly applicable to the vaccine design process. ClustiMer, an ancillary algorithm 
used with EpiMatrix, maps MHC motif matches along the length of a protein and calculates the density of motifs for 
eight common class II HLA alleles: DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0701, DRB1*0801, 
DRB1*1101, DRB1*1301 and DRB1*1501. Typical T-cell epitope 'clusters' range from 9 to roughly 25 amino acids 
in length and, considering their affinity to multiple alleles and across multiple frames, can contain anywhere from 4 
to 40 binding motifs, also known as promiscuous epitopes. 
The Conservatrix algorithm identifies conserved segments from among any given set of variable protein 
isolates. Pairing EpiMatrix with Conservatrix allows users to identify peptides, which are both potentially antigenic 
and conserved in circulating disease strains. BlastiMer compares a peptide’s sequence to the human proteome to 
ensure that it does not contain too much homology to any human protein. The Aggregatrix algorithm addresses the 
classical “set cover” problem by guiding the selection of a portfolio of epitopes that collectively “cover” a wide 
variety of both the known circulating strain variants of a given pathogen and the majority of common human HLA 
types. OptiMatrix is an algorithm that is used for designing altered peptide ligands that optimize the “aggretope.” 
Specifically, OptiMatrix guides strategic substitutions of the MHC-contact residues such that the peptide binds more 
strongly; the TCR-facing residues are free to interact as they would in the unaltered peptide. The VaccineCAD
algorithm arranges putative T-cell epitopes to create optimized “string-of-beads” vaccine immunogens. The 
EpiAssembler algorithm was developed especially for use with highly variable RNA viruses. It is used to analyze 
the universe of viral isolates and to create composite epitope sequences whose constituent overlapping epitopes are 
both highly conserved and highly immunogenic [27]. Taken collectively, these tools allow researchers to quickly 
and effectively identify T-cell epitopes and design new antigens for experimental study, as illustrated in the next 
three sections. 
EpiVax’ immunoinformatics toolkit has been used to rank proteins for potential immunogenicity [35,36] and to 
design and evaluate vaccines [37,38]. We note that Korber et al. recently implemented very similar tools for the 
design of HIV-1 vaccines [39]. Over the course of a decade of research, the EpiVax tools have been validated in 
vitro and in vivo. The tools are currently in use for both vaccine and protein therapeutics design [4041 4243-44]. In the next 
few paragraphs, we summarize data showing that prototype ID-ED vaccines, developed using the EpiVax vaccine 
design toolkit, provide protection against lethal challenge with vaccinia, tularemia, and in a model of chronic 
H.pylori infection. We describe the tools that made these successes possible and discuss the anticipated clinical 
development of ID-ED vaccines.
2. New immunome-derived, epitope-driven vaccines: protection against challenge
2.1. ID-EDV for F. tularensis (TuliVax)
Francisella tularensis causes the potentially fatal disease, tularemia, which is of great concern in regions of the 
world where tularemia is endemic and, in addition, because of the potential for its use in a bioterror attack. We 
employed the genome-to-vaccine strategy to develop a T-cell epitope-based tularemia vaccine. The EpiMatrix 
epitope-mapping algorithm was used to identify promiscuous T-cell epitopes within secreted proteins predicted from 
an analysis of the F. tularensis subsp. tularensis genome; T-cell epitopes within known expressed proteins were also 
identified. The top-scoring 40 putative promiscuous class II epitopes were screened in vitro using a recombinant 
soluble HLA class II competition binding assay. High affinity epitopes were tested in ELISpot assays using blood 
from human subjects that had recovered from F. tularensis tularensis infection. Soluble DRB1*0101 bound 42% of 
the predicted class II peptides with high affinity. ELISpot assays, performed using blood from tularemia infected 
patients, showed positive IFN-gamma responses to 21 of 25 individual Class II peptides and to peptide pools. 
Fourteen Class II epitope sequences that elicited a robust response in these two assays were incorporated into a 
DNA vaccine construct. DRB1*0101 transgenic mice were immunized with the multi-epitope construct, boosted 
with epitope peptides formulated in liposomes with CpG oligonucleotides, then challenged intratracheally with a 
lethal dose of the F. tularensis vaccine strain. 
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Splenocytes from mice vaccinated with the string-of-beads DNA vaccine construct, followed by boosting with 
peptides in liposomes (with CpG), showed a higher response to the vaccine peptides than did splenocytes from sham 
control mice. These responses correlated with protection: >50% of immunized mice survived respiratory challenge 
with 5xLD50 of live, attenuated F. tularensis subsp. holarctica (LVS) while all non-immunized mice died. This 
study demonstrated that T-cell epitopes predicted from the F. tularensis genome could protect against live aerosol 
challenge in a humanized small animal model [45]. An improved vaccine with additional F. tularensis tularensis
epitopes is currently under evaluation in mice challenged with the more virulent SchuS4 strain of F. tularensis.
2.2. ID-EDV for Smallpox (VennVax)
To develop a novel, safer smallpox vaccine that could be used alone or in combination with existing attenuated 
vaccines (MVA, ACAM2000), we screened three variola genomes and four vaccinia genomes for conserved 
candidate epitopes using EpiMatrix, ClustiMer and Conservatrix. Our approach to this problem was as follows: 
908,040 9-10mer peptides from 1,472 non-redundant genes were examined with our Conservatrix and EpiMatrix 
tools and 10,147 (6%) were found to be conserved in all strains and potentially immunogenic. We selected 110 of 
the conserved (Venn-diagramed, hence VennVax) epitopes for vaccine design, of which 50 were promiscuous Class
II epitopes, 40 were Class I HLA A2 and 20 were Class I B7. Ninety-one percent of epitopes were confirmed in 
ELISpot assays using blood from Dryvax immunized volunteers. Epitopes were engineered into string-of-beads 
multi-epitope genes using VaccineCAD and subcloned into pVAX1. This prototype vaccine is called the VennVax 
smallpox vaccine as it incorporates epitopes at the intersection of the variola and vaccinia immunomes.
Initially, DRB1*0101 transgenic mice were immunized intramuscularly with the VennVax DNA construct and 
boosted subcutaneously with the corresponding peptides (in liposomes with CpG). In a follow up study, two groups 
of DRB1*0301 transgenic mice were intramuscularly immunized and boosted intranasally with peptides formulated 
in liposomes with CpG oligodeoxynucleotide. Immunogenicity was measured by IFN ELISpot. Variola/vaccinia 
epitopes that stimulated >20 SFC/10
6
 splenocytes in comparison with non-immunized mice (p<0.01) were 
considered immunogenic. Immunization of DRB1*0101 transgenic mice stimulated significant T cell responses to 6 
of 25 epitopes (24%). In comparison, DRB1*0301 mice immunized with the same 25-epitope set responded to 10 
(40%) of epitopes, of which two were also reactive in DRB1*0101 mice. A vaccine encoding a second set of 25 
epitopes stimulated significant responses for 8 (32%) epitopes in DRB1*0301 mice. In this study, more
variola/vaccinia epitopes were confirmed for less cost and in less time than two previously published studies 
[46,47]. Immunization with the fifty epitope VennVax DNA vaccine followed by boosting with peptide-in-liposome 
provided 100% efficacy against aerosolized vaccinia challenge. Prior to challenge, antibodies to vaccinia were not 
detectable in the vaccinated mice. To our knowledge, the 100% protective VennVax vaccine is the only effective T
cell epitope-based vaccine described for vaccinia, to date. The next phase of VennVax vaccine development will 
involve testing efficacy of the DNA prime with vaccinia boost in a monkeypox model.
2.3. ID-EDV for H. pylori (HelicoVax)
Using EpiMatrix, open reading frames (ORFs) that are highly conserved between H. Pylori human strains J99 
and 26695 were analyzed for T-cell epitope clusters with motifs for HLA Class II and the mouse I-Ab alleles. Fifty 
epitopes were incorporated into “HelicoVax”, a DNA-prime/peptide-boost vaccine. HelicoVax was tested in p27
-/-
C57BL/6 mice pre-infected with murine-adapted SS1 strain, a novel model for H. pylrori–associated gastric 
carcinogenesis [48]. Immunogenicity and modulation of immune response were measured 45 weeks post-
immunization. We identified 1,152 epitope clusters from 1,107 conserved ORFs. From the top 150 epitopes, 50 
were selected for vaccine formulation based on their high affinity for HLA DR1, defined by >50% inhibition of 
reference peptide at 10 mM in a competition assay. Interferon-gamma ELISpot assays of epitope-stimulated 
splenocytes demonstrated that 47/50 peptides (94%) were immunogenic following IN or IM DNA immunization 
with the multi-epitope vaccine as compared with only 4/50 epitopes recognized in SS1 lysate-immunized animals. 
Pathology results and culture results are pending. In addition, mice infected with H. pylori displayed reduced 
regulatory T cell populations (CD4+ CD25+ double positive cells) among both splenocytes (41% reduction, 
p=0.098) and mesenteric lymph node cells (35% reduction, p=0.026) compared to non-exposed mice. Similar 
reductions in numbers of Tregs were seen among mice immunized with SS1 lysate (splenocytes: 48% reduction 
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p=0.02; lymph node cells: 28% reduction p=0.036). This is an important observation as suppression of immune 
response is considered one of the factors that contribute to the carcinogenic properties of H. pylori infection. 
Additional studies are planned which will explore the development of gastric cancer in H.pylori-exposed, 
HelicoVax- immunized mice. 
3. Conclusion
In the cancer vaccine field, where the concept of T-cell epitope-driven vaccines is well accepted, a number of 
epitope-driven vaccines have successfully passed preclinical tests and are either currently in Phase I/II clinical trials 
or trials are soon to be initiated. By contrast, the immunome-derived, epitope-driven vaccine approach has been less 
frequently pursued for microbial pathogens, and as a consequence, few such vaccines have reached the stage of 
Phase I or II efficacy trials in humans [49,50]. 
Indeed, banner headlines about the failure of the Merck HIV vaccine have dampened enthusiasm about vaccines 
that evoke T-cell epitope-driven immune responses for human pathogens [51]. To better understand the reason for 
the failure of that or other similar “T-cell directed” vaccines, it is important to remember that the breadth and the 
quality of the immune response play important roles in vaccine efficacy. In the context of HIV, better-designed 
immunogens (such as the cross-conserved epitopes identified for the GAIA Vaccine [27,52,53]) should improve the 
efficacy against ‘wild type’ HIV transmitted in human populations. Therefore, rather than abandon all hope based on 
the failure of the two best known “T-cell-directed” HIV vaccines [54,55], we and others believe that carefully 
designed epitope-driven vaccines will provide a successful means of vaccinating against HIV [56]. 
So as to improve on previous vaccines, future epitope-driven vaccines (against HIV and other human pathogens) 
should (1) expand on the number of epitopes contained in the vaccines, (2) pay careful attention to sequence
conservation with clinical strains, (3) expand HLA population coverage, and (4) improve the vaccine delivery 
vehicle. Route of delivery also appears to be an important factor, particularly when the infection is by a mucosal 
route. These important factors that contribute to the success of a vaccine can be summarized as follows: 
Immunogen + Adjuvant + Delivery vehicle = Vaccine.
One means of addressing immunogen quality is to include more epitopes. Evidence from animal studies suggests 
that the number of epitopes required for full protection is a small and definable subset [57,58]. Careful selection of 
promiscuous Class II epitopes and Class I supertype epitopes can provide greater than 99% coverage of human 
populations [59]. An effective ID-ED vaccine for humans may need to include at least 50 Class I and Class II 
broadly HLA-restricted (promiscuous) epitopes. Another means of improving the immunogenicity of an ID-EDV is 
to choose epitopes that induce multi-functional T cell responses in human PBMC [60]. Careful selection of vaccine 
delivery vehicle, route and formulation will improve immunogenicity and may also improve the likelihood of 
successful protection against disease.
The availability of higher-quality, validated vaccine design tools, such as the ones described here, enable the 
effective selection of highly immunogenic, cross-conserved T-cell epitopes. The delivery of these epitopes by the 
right route, in properly designed constructs and effective delivery vehicles, with the right adjuvant is likely to 
improve immunome-derived epitope-driven vaccine success and lead to important public health breakthroughs for 
future generations. 
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